ArticleTherapeutic advances in gastroenterology2024

First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis.

Jianying Lei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.